NRSN
Neurosense Therapeutics Ltd
NASDAQ: NRSN · HEALTHCARE · BIOTECHNOLOGY
$0.80
-0.72% today
Updated 2026-04-29
Market cap
$26.53M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.44
Dividend yield
—
52W range
$1 – $3
Volume
0.2M
Neurosense Therapeutics Ltd (NRSN) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-582000.00 | $-695000.00 | $-1.54M | $-7.59M | $-8.35M | $-10.13M | $-7.67M |
| Capital expenditures | $7000.00 | $9000.00 | $17000.00 | $70000.00 | $29000.00 | $3000.00 | $8000.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $611000.00 | $2.06M | $4.16M | $5.11M | $1.54M | $557000.00 | $2.14M |
| Free cash flow | $-589000.00 | $-704000.00 | $-1.56M | $-7.66M | $-8.38M | $-10.14M | $-7.68M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — |